Late-breaking clinical trials presented at the 2005 and 2006 annual scientific meetings of
the ACC, AHA, and European Society of Cardiology, as well as selected other data, were …

Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

The ACC/AHA Task Force on Practice Guidelines was formed to make recommendations
regarding the diagnosis and treatment of patients with known or suspected cardiovascular …

The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular …

… Krumholz … Krumholz … Krumholz …

The process of guideline development for management of patients with acute myocardial
infarction (AMI) has undergone substantial evolution since the inaugural publication entitled “…

Late-breaking clinical trials presented at the 2007 and 2008 annual scientific meetings of the
ACC, AHA, Transcatheter Cardiovascular Therapeutics, the European Society of Cardi-

• Ask about tobacco use status at every visit. I (B)• Advise every tobacco user to quit. I (B)•
Assess the tobacco user’s willingness to quit. I (B)• Assist by counseling and developing a plan …